WB Kim, D Jerome, J Yeung - Canadian Family Physician, 2017 - cfp.ca
Objective To provide primary care clinicians with an up-to-date and practical overview of the diagnosis and management of psoriasis. Quality of evidence PubMed, MEDLINE, EMBASE …
CA Elmets, CL Leonardi, DMR Davis… - Journal of the American …, 2019 - Elsevier
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities - ScienceDirect Skip to main contentSkip to article …
PJ Mease, IB McInnes, B Kirkham… - … England Journal of …, 2015 - Mass Medical Soc
Background In a phase 2 study, the inhibition of the interleukin-17A receptor improved signs and symptoms of psoriatic arthritis. We sought to evaluate the efficacy and safety of …
Background Ixekizumab is a humanised monoclonal antibody against the proinflammatory cytokine interleukin 17A. We report two studies of ixekizumab compared with placebo or …
G Girolomoni, R Strohal, L Puig… - Journal of the …, 2017 - Wiley Online Library
Psoriasis is a chronic, immune‐mediated disease affecting more than 100 million people worldwide and up to 2.2% of the UK population. The aetiology of psoriasis is thought to …
Background Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has demonstrated efficacy and safety in patients with moderate to severe plaque psoriasis …
Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease. Up to 40% of patients with psoriasis will go on to develop PsA, usually within 5–10 years of cutaneous disease …
BC Palmer, LA DeLouise - Molecules, 2016 - mdpi.com
Transdermal drug delivery systems have been around for decades, and current technologies (eg, patches, ointments, and creams) enhance the skin permeation of low …
AW Armstrong, MP Siegel, J Bagel, EE Boh… - Journal of the American …, 2017 - Elsevier
Background An urgent need exists in the United States to establish treatment goals in psoriasis. Objective We aim to establish defined treatment targets toward which clinicians …